Security key
23284F105
CytomX Therapeutics, Inc. - Common Stock (CTMX)
CUSIP: 23284F105
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 193,169,653
- Total 13F value
- $907,862,078
- Share change
- +46,088,761
- Put/Call ratio
- 67%
- SEC-reported price per share
- $4.70
- Number of holders
- 179
- Value change
- +$226,816,911
- Number of buys
- 127
- Number of sells
- 46
- Shares outstanding
- 216,209,843
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
179
Top holders
10
CTMX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
CytomX Therapeutics, Inc. SEC filings
CytomX Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 23284F105
Recent filing periods:
Ownership snapshot
Top reported holders of CTMX - CytomX Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
Longitude Capital Partners V, LLC
7%
Kynam Capital Management, LP
6.9%
PERCEPTIVE ADVISORS LLC
4.6%
Venrock Healthcare Capital Partne...
4.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$105,171,344
24,688,109 shares
|
+$17,756,285 | 31 Dec 2025 |
| Longitude Capital Partners V, LLC |
13D/G
Patrick G. Enright
|
7%
|
$65,740,382
15,288,461 shares
|
+$16,125,000 | 31 Mar 2026 |
| Kynam Capital Management, LP |
13F
13D/G
Company
|
6.9%
from 13D/G
|
$38,195,488
8,966,077 shares
|
— | 31 Dec 2025 |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
Company
|
4.6%
|
$43,424,943
10,098,824 shares
|
+$1,800,148 | 31 Mar 2026 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
4.6%
|
$42,923,133
9,982,124 shares
|
-$23,991,317 | 31 Mar 2026 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
3.5%
|
$17,250,001
5,769,231 shares
|
-$17,250,001 | 03 Jul 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
179
Shares
193,169,653
Rows available
179
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q1 2026 Across Filers
Q1 2026 holders
179
Q1 2026 holders
179
Holder diff
0
| Investor | Q1 2026 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q1 2026 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend